×
About 94,698 results

ALLMedicine™ Small Cell Lung Cancer Center

Research & Reviews  43,811 results

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analy...
https://doi.org/10.1002/cam4.3732
Cancer Medicine; Parker JL, Kuzulugil SS et. al.

Feb 23rd, 2021 - To date there has not been an extensive analysis of the outcomes of biomarker use in oncology. Data were pooled across four indications in oncology drawing upon trial outcomes from www.clinicaltrials.gov: breast cancer, non-small cell lung cancer ...

Predicting lung adenocarcinoma prognosis with a novel risk scoring based on platelet-re...
https://doi.org/10.18632/aging.202682
Aging Zhou C, Wang Y et. al.

Feb 23rd, 2021 - Lung adenocarcinoma is the most common subtype of non-small cell lung cancer, and platelet receptor-related genes are related to its occurrence and progression. A new prognostic indicator based on platelet receptor-related genes was developed with...

CircVAPA exerts oncogenic property in non-small cell lung cancer by the miR-876-5p/WNT5...
https://doi.org/10.1002/jgm.3325
The Journal of Gene Medicine; Zhao Y, Dai Q et. al.

Feb 23rd, 2021 - Non-small cell lung cancer (NSCLC) is one of the most fatal malignant tumors. Emerging studies have clarified the crucial roles of circular RNAs (circRNAs) in the tumorigenesis of cancers. CircVAPA was demonstrated to function in some human cancer...

Prediction of the Therapeutic Effects of Pembrolizumab and Nivolumab in Advanced Non-Sm...
https://doi.org/10.1177/1533033821997817
Technology in Cancer Research & Treatment; Liu T, Wang J et. al.

Feb 22nd, 2021 - There are limited methods to predict the therapeutic effect of immune checkpoint inhibitors (ICIs). The purpose of this study was to explore the value of circulating microparticles (MPs) in predicting thetherapeutic effects of immunotherapy. A pro...

Overexpression of hsa_circ_0002874 promotes resistance of non-small cell lung cancer to...
https://doi.org/10.18632/aging.202521
Aging Xu J, Ni L et. al.

Feb 22nd, 2021 - This study aimed to investigate the aberrant expression of hsa_circ_0002874 in non-small cell lung cancer (NSCLC) and elucidate associated molecular mechanisms that influence apoptosis and induce paclitaxel (PTX) resistance. Inhibitors were used t...

see more →

Guidelines  257 results

Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors
https://pubmed.ncbi.nlm.nih.gov/32746691/
Journal of Oncology Pharmacy Practice; Rosentreter J

Aug 2nd, 2020 - Cancer patients tend to prefer oral instead of parenteral chemotherapy. To date, there is little evidence on the medication adherence in cancer patients. We investigated medication adherence to tyrosine kinase inhibitors in patients suffering from...

Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3...
https://www.jto.org/article/S1556-0864(20)30595-5/pdf
Journal of Thoracic Oncology; Yang Y

Jul 24th, 2020 - Sintilimab, an anti-programmed death 1 antibody, plus pemetrexed and platinum had shown promising efficacy for nonsquamous non-small cell lung cancer in a phase 1b study. We conducted a randomized, double-blind, phase 3 study to compare the ef...

Will DFS Benefit Translate Into Survival Benefit in ADAURA?
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200221/full/

Jun 23rd, 2020 - The report on ADAURA during the ASCO20 Virtual Scientific Program Plenary Session surprised many, first because the initial data readout for the phase III trial was not planned until 2022 and second because of the strength of the disclosed data (A...

FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer
FDA

Jun 14th, 2020 - On June 15, 2020, the Food and Drug Administration granted accelerated approval to lurbinectedin(ZEPZELCA, Pharma Mar S.A.) for adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemot...

Updated Data Displays Better OS With Use of Alectinib Over Crizotinib in ALK+ NSCLC
https://www.targetedonc.com/view/updated-data-displays-better-os-with-use-of-alectinib-over-crizotinib-in-alk-nsclc

May 30th, 2020 - Patients with ALK-positive non–small cell lung cancer (NSCLC) showed clinically meaningful improvement in overall survival (OS) when receiving alectinib (Alecensa), a highly selective second-generation TKI, versus those treated with crizotinib (Xa...

see more →

Drugs  317 results see all →

Clinicaltrials.gov  47,811 results

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analy...
https://doi.org/10.1002/cam4.3732
Cancer Medicine; Parker JL, Kuzulugil SS et. al.

Feb 23rd, 2021 - To date there has not been an extensive analysis of the outcomes of biomarker use in oncology. Data were pooled across four indications in oncology drawing upon trial outcomes from www.clinicaltrials.gov: breast cancer, non-small cell lung cancer ...

Predicting lung adenocarcinoma prognosis with a novel risk scoring based on platelet-re...
https://doi.org/10.18632/aging.202682
Aging Zhou C, Wang Y et. al.

Feb 23rd, 2021 - Lung adenocarcinoma is the most common subtype of non-small cell lung cancer, and platelet receptor-related genes are related to its occurrence and progression. A new prognostic indicator based on platelet receptor-related genes was developed with...

CircVAPA exerts oncogenic property in non-small cell lung cancer by the miR-876-5p/WNT5...
https://doi.org/10.1002/jgm.3325
The Journal of Gene Medicine; Zhao Y, Dai Q et. al.

Feb 23rd, 2021 - Non-small cell lung cancer (NSCLC) is one of the most fatal malignant tumors. Emerging studies have clarified the crucial roles of circular RNAs (circRNAs) in the tumorigenesis of cancers. CircVAPA was demonstrated to function in some human cancer...

Prediction of the Therapeutic Effects of Pembrolizumab and Nivolumab in Advanced Non-Sm...
https://doi.org/10.1177/1533033821997817
Technology in Cancer Research & Treatment; Liu T, Wang J et. al.

Feb 22nd, 2021 - There are limited methods to predict the therapeutic effect of immune checkpoint inhibitors (ICIs). The purpose of this study was to explore the value of circulating microparticles (MPs) in predicting thetherapeutic effects of immunotherapy. A pro...

Overexpression of hsa_circ_0002874 promotes resistance of non-small cell lung cancer to...
https://doi.org/10.18632/aging.202521
Aging Xu J, Ni L et. al.

Feb 22nd, 2021 - This study aimed to investigate the aberrant expression of hsa_circ_0002874 in non-small cell lung cancer (NSCLC) and elucidate associated molecular mechanisms that influence apoptosis and induce paclitaxel (PTX) resistance. Inhibitors were used t...

see more →

News  2,491 results

Bladder Cancer Indication Withdrawn for Durvalumab
https://www.medscape.com/viewarticle/946293

Feb 22nd, 2021 - After failing to improve overall survival in unresectable metastatic bladder cancer in a phase 3 trial, this indication will be withdrawn in the United States for the immunotherapy durvalumab (Imfinzi), AstraZeneca announced. The withdrawal does n...

First Drug That Protects Against Chemo-Induced Myelosuppression
https://www.medscape.com/viewarticle/945820

Feb 14th, 2021 - A novel drug that offers multilineage protection from chemotherapy-induced myelosuppression has been approved by the US Food and Drug Administration. The drug, trilaciclib (Cosela, G1 Therapeutics) is administered intravenously as a 30-minute infu...

ASCO Endorses Guidelines on Radiation Therapy for SCLC
https://www.medscape.com/viewarticle/945724

Feb 11th, 2021 - Takeaway The American Society of Clinical Oncology (ASCO) has endorsed guidelines on radiation therapy (RT) for patients with small cell lung cancer (SCLC), addressing thoracic radiotherapy for limited-stage SCLC, stereotactic body radiotherapy (S...

Amivantamab Shows Promise in Challenging EGFR-Mutated NSCLC
https://www.medscape.com/viewarticle/945643

Feb 10th, 2021 - A novel drug, the immune cell-directing antibody amivantamab (under development by Janssen), has shown promise for the treatment of patients with non–small cell lung cancer (NSCLC) with exon 20 insertion mutations in the epidermal growth factor re...

Neoadjuvant Atezolizumab Safe in Resectable Lung Cancer
https://www.medscape.com/viewarticle/945607

Feb 9th, 2021 - Neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients with stage IB-IIIB lung cancer and produced a 21% major pathologic response rate, according to the primary analysis of the Lung Cancer Mutation Consortium (LCMC) ...

see more →

Patient Education  11 results see all →